Mettler-Toledo International Inc. experienced a price increase of 3.00%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.87% and the S&P 500 up 0.60%.
This rise is attributed to Mettler-Toledo's upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, where the company will showcase its innovative solutions in life sciences, food, and chemicals. This event is expected to enhance investor engagement and attract potential investors, reinforcing the company's market leadership.
The implications of this presentation are significant, as Mettler-Toledo's strong global market position and commitment to innovation are likely to drive future sales growth and expand its market share in the precision instruments sector.
Wall Street analysts forecast MTD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTD is 1515 USD with a low forecast of 1444 USD and a high forecast of 1600 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast MTD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTD is 1515 USD with a low forecast of 1444 USD and a high forecast of 1600 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 1401.640
Low
1444
Averages
1515
High
1600
Current: 1401.640
Low
1444
Averages
1515
High
1600
Barclays
Overweight
downgrade
2025-12-15
Reason
Barclays
Price Target
AI Analysis
2025-12-15
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Mettler-Toledo to $1,550 from $1,600 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
BofA
Neutral
to
Buy
upgrade
2025-12-15
Reason
BofA
Price Target
2025-12-15
upgrade
Neutral
to
Buy
Reason
BofA upgraded Mettler-Toledo to Buy from Neutral with a price target of $1,600, up from $1,500.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MTD
Unlock Now
Wells Fargo
Equal Weight
maintain
2025-12-15
Reason
Wells Fargo
Price Target
2025-12-15
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Mettler-Toledo to $1,450 from $1,400 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Goldman Sachs
Neutral
initiated
$1,475
2025-12-09
Reason
Goldman Sachs
Price Target
$1,475
2025-12-09
initiated
Neutral
Reason
Goldman Sachs initiated coverage of Mettler-Toledo with a Neutral rating and $1,475 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.
About MTD
Mettler-Toledo International Inc. is a supplier of precision instruments and services. The Company manufactures a variety of precision instruments and provides value-added services to its customers. Its principal products and services include laboratory instruments, industrial instruments, and retail weighing solutions. The Company makes a variety of precision laboratory instruments for sample preparation, synthesis, analytical bench top, material characterization, and in-line measurement. Its portfolio includes laboratory balances, liquid pipetting solutions, automated laboratory reactors including real-time analytics, titrators, pH meters, and other analytical instruments. It manufactures numerous industrial weighing instruments and related terminals, and offers software solutions for the pharmaceutical, chemical, food, discrete manufacturing, and other industries. It offers weighing and software solutions, which can integrate counter, self-service, backroom and checkout functions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
